1. Home
  2. CCSI vs TRDA Comparison

CCSI vs TRDA Comparison

Compare CCSI & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Consensus Cloud Solutions Inc.

CCSI

Consensus Cloud Solutions Inc.

HOLD

Current Price

$23.42

Market Cap

433.5M

Sector

Technology

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$10.44

Market Cap

386.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCSI
TRDA
Founded
2021
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
433.5M
386.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
CCSI
TRDA
Price
$23.42
$10.44
Analyst Decision
Hold
Strong Buy
Analyst Count
3
1
Target Price
$29.00
$20.00
AVG Volume (30 Days)
187.0K
179.2K
Earning Date
11-05-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
4.22
N/A
Revenue
$349,609,000.00
$61,520,000.00
Revenue This Year
$1.67
N/A
Revenue Next Year
$0.97
$3.14
P/E Ratio
$5.53
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.84
$4.93
52 Week High
$32.10
$18.76

Technical Indicators

Market Signals
Indicator
CCSI
TRDA
Relative Strength Index (RSI) 51.12 55.88
Support Level $22.38 $10.31
Resistance Level $23.64 $11.55
Average True Range (ATR) 0.76 0.55
MACD 0.11 -0.17
Stochastic Oscillator 63.69 10.08

Price Performance

Historical Comparison
CCSI
TRDA

About CCSI Consensus Cloud Solutions Inc.

Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in fax cloud business. The Company operates in USA, Canada, Ireland, and Other. Geographically, it derives a maximum revenue from the United States. The company's communication and digital signature solutions enable customers to securely and cooperatively access, exchange and use information across organizational, regional, and national boundaries.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: